Klin Farmakol Farm. 2020;34(2):74-77 | DOI: 10.36290/far.2020.015
Monoclonal antibodies in pregnant women with inflammatory bowel disease
- Centrum péče o zažívací trakt. Vítkovická nemocnice, a. s., Ostrava
- II. interní klinika - gastroenterologická a geriatrická LF UP a FN Olomouc
- Lékařská fakulta Ostravské univerzity, Ostrava
Crohn´sdisease and ulcerative colitis are inflammatory bowel diseases which affect mainly young people in their reproductive age. Anti-TNF treatment presents the first type of biological treatment of IBD and its safety during pregnancy is already documented by numerous observational studies. However, in recent years, the spectrum of biological treatment of IBD has expanded owing to two new monoclonal antibodies with different mechanisms of effect: vedolizumab (humanized monoclonal antibody against leukocyte integrin receptors α4β7) and ustekinumab (human monoclonal IgG1 antibody against interleukin IL 12/23 unit). Nonetheless, due to the small number of patients, the data are still limited and further monitoring is required.
Keywords: inflammatory bowel disease, pregnancy, monoclonal antibodies, adalimumab, infliximab, vedolizumab, ustekinumab.
Published: July 16, 2020 Show citation
References
- Ahluwalia B, Moraes L, Magnusson MK, Öhman L. Immunopathogenesis of inflammatory bowel disease and mechanisms of biological therapies. Scand J Gastroenterol 2018; 53: 379-389.
Go to original source... - Minárikova P. Současné možnosti medikamentózní léčby idiopatických střevních zánětů. Medicína po promoci 2019; 3: 201-204.
- Douda T. Fertilita, gravidita a kojenî u nemocných s idiopatickými střevnîmi záněty. Remedia 2017; 27: 384-388.
- Jarkovský J, Benešová K, Hejduk K, et al. Epidemiology, hospitalization and migration of patients with IBD under specialized care in the Czech Republic. Gastroent Hepatol 2017; 71: 501-509. Go to original source...
- Burisch J, Pedersen N, Cučkovič-Čavka S, et al. East‑West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO‑EpiCom inception cohort. Gut 2014; 63: 588-597. Go to original source...
Go to PubMed... - Woude CJ, Ardizzone S, et al. The second European evidenced‑based consensus on reproduction and pregnancy in inflammatory bowel disease. J Crohns Colitis. 2015; 9(2): 107-124. Go to original source... Go to PubMed...
- Lukáš M. Obecné principy biologické léčby u IBD. In: Pavelka K et al (eds). Biologická léčba zánětlivých autoimunitních onemocnění. Praha: Grada 2014: 253-264.
- Bortlik M, Machkova N, Duricova D, et al. Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti‑TNF‑α therapy during pregnancy: three‑center study. Scand J Gastroenterol. 2013; 48(8): 951-958. Go to original source... Go to PubMed...
- Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013; 369(8): 699-710. Go to original source...
- Moens A, van Hoeve K, Humblet E, et al. Outcome of Pregnancies in Female Patients With Inflammatory Bowel Diseases Treated With Vedolizumab. J Crohns Colitis. 2018. Go to original source...
- Mahadevan U, Vermeire S, Lasch K, et al. Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease. Aliment Pharmacol Ther. 2017; 45(7): 941-950. Go to original source...
- Rowan CR, Cullen G, Mulcahy HE, et al. Ustekinumab Drug Levels in Maternal and Cord Blood in a Woman With Crohn's Disease Treated Until 33 Weeks of Gestation. J Crohns Colitis. 2018; 12(3): 376-378. Go to original source... Go to PubMed...
- Lund T, Thomsen SF. Use of TNF‑inhibitors and ustekinumab for psoriasis during pregnancy: A patient series. Dermatol Ther. 2017; 30(3). Go to original source...
- Vermeire S, Carbonnel F, Coulie PG, et al. Management of inflammatory bowel disease in pregnancy. J Crohns Colitis 2012; 6: 811-823. Go to original source... Go to PubMed...
- Zbořil V, a kol. Idiopatické střevní záněty. Praha: Mladá fronta, 2018.
- Mahadevan U, Martin CF, Chambers C, et al. Achievement of developmental milestones among off- spring of women with inflammatory bowel disease: The PIANO Registry. Gastroenterology 2014; 146: S-1. Go to original source...
- Bortlík M, Ďuricová D, Douda T, et al. Doporučení pro podávání biologické léčby pacientům s idiopatickými střevními záněty: čtvrté, aktualizované vydání. Gastroent Hepatol 2019; 73(1): 11-24. Go to original source...
- Nielsen O, et al. Safety of TNF-α inhibitors during IBD pregnancy: a systematic review. BMC Med 2013; 11: 174. Go to original source... Go to PubMed...
- Bortlík M, Ďuricová D, Kohout P, et al. Doporučení pro podávání biologické terapie u idiopatických střevních zánětů: třetí, aktualizované vydání. Gastroent Hepatol 2016; 70: 11-26. Go to original source...
- Bortlik M, Duricova D, Machkova N, et al. Impact of anti-tumor necrosis factor alpha antibodies administered to pregnant women with inflammatory bowel disease on long-term outcome of exposed children. Inflamm Bowel Dis 2014; 20: 495-501. Go to original source... Go to PubMed...
- Mahadevan U, Wolf DC, Dubinsky M, et al. Placental transfer of anti‑tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013; 11(3): 286-292. Go to original source...
- Scherl E, Jacobstein D, Murphy C, et al. A109 Pregnancy outcomes in women exposed to ustekinumab in the Crohn's disease clinical development program. J Canadian Assotiation Gastroenterology 2018; l(Suppl 2): 166. Go to original source...
- Julsgaard M, Kjeldsen J, Brock B, et al. Letter: vedolizumab drug levels in cord and maternal blood in women with inflammatory bowel disease. Aliment Pharmacol Ther 2018; 48(3): 386-388. Go to original source...